Skip to main content

Table 5 Incident rates and median time for T2DM diagnosis at different follow-up times, according to hypertension and CVD diagnosis

From: Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink

  

Statin use

  

Yes

No

Follow up time (years) PS [5-95%] (N = 1,448,993)

Hazard ratio (95% CI)*

Incident T2DM per 1000 person-years (95% CI)

Nº T2DM /Median time (days)

Incident T2DM per 1000 person-years (95% CI)

Nº T2DM /Median time (days)

Total sample

0-1 yr

1.52 (1.47-1.57)

19.97 (19.52-20.42)

7,634/139

11.53 (11.33-11.74)

12,189/210

1-3 yr

1.22 (1.19-1.25)

20.11 (19.78-20.44)

13,786/727

13.35 (13.34-13.37)

21,418/644

3-5 yr

1.73 (1.68-1.80)

24.56 (24.12-25.00)

11,858/1,440

11.61 (11.38-11.84)

9,773/1,394

5-10 yr

2.25 (2.17-2.34)

30.03 (29.55-30.53)

14,523/2,450

10.85 (10.59-11.12)

6,534/2,312

10-15 yr

3.05 (2.71-3.43)

34.93 (33.53-36.39)

2,292/4,174

10.20 (9.38-11.10)

543/4,166

15-20 yr

3.63 (2.44-5.38)

42.24 (36.90-48.36)

210/5,877

12.24 (9.10-16.51)

43/5,773

20-25 yr

n.e.

13.10 (1.84-93.00)

1/ -

0

0/ -

No hypertension

0-1 yr

2.05 (1.96-2.15)

19.53 (18.97-20.11)

4,486/134

8.65 (8.44-8.85)

6,893/215

1-3 yr

1.50 (1.45-1.55)

18.64 (18.23-19.06)

7,694/727

10.60 (10.42-10.77)

13,114/653

3-5 yr

2.00 (1.92-2.09)

22.15 (21.61-22.69)

6,463/1,439

9.56 (9.33-9.80)

6,550/1,400

5-10 yr

2.50 (2.39-2.61)

27.65 (27.06-28.24)

8,502/2,482

9.32 (9.06-9.59)

4,750/2,335

10-15 yr

3.14 (2.75-3.58)

32.86 (31.26-34.55)

1,541/4,180

9.31 (8.48-10.21)

446/4,186

15-20 yr

3.84 (2.52-5.86)

41.61 (35.64-48.59)

160/5,877

11.55 (8.41-15.88)

38/5,780

20-25 yr

n.e.

0

0/ -

0

0/ -

Hypertension

0-1 yr

0.96 (0.91-1.01)

20.62 (19.91-21.35)

3,148/145

20.40 (19.86-20.96)

5,296/204

1-3 yr

0.84 (0.81-0.88)

22.33 (21.77-22.89)

6,092/726

24.20 (23.68-24.72)

8,304/625

3-5 yr

1.22 (1.15-1.29)

28.24 (27.50-29.00)

5,395/1,442

20.51 (19.82-21.23)

3,223/1,380

5-10 yr

1.56 (1.46-1.67)

34.22 (33.37-35.10)

6,021/2,405

19.25 (18.38-20.17)

1,784/2,264

10-15 yr

2.19 (1.68-2.84)

40.09 (37.32-43.06)

751/4,156

18.33 (15.02-22.37)

97/4,073

15-20 yr

2.32 (0.77-7.01)

44.38 (33.64-58.56)

50/5,876

22.38 (9.31-53.77)

5/ -

20-25 yr

n.e.

0

0/ -

0

0/ -

No CVD

0-1 yr

1.74 (1.67-1.80)

20.72 (20.22-21.24)

6,260/136

10.74 (10.54-10.95)

10,474/213

1-3 yr

1.31 (1.28-1.35)

20.37 (19.99-20.75)

11,037/725

12.93 (12.75-13.11)

19,254/647

3-5 yr

1.85 (1.78-1.92)

24.94 (24.44-25.45)

9,325/1,438

11.18 (10.95-11.42)

9,022/1,393

5-10 yr

2.34 (2.24-2.43)

30.44 (29.86-31.02)

10,512/2,416

10.56 (10.30-10.83)

6,134/2,317

10-15 yr

2.96 (2.61-3.35)

33.58 (31.85-35.97)

1,379/4,151

10.08 (9.26-10.99)

523/4,166

15-20 yr

3.76 (2.49-5.67)

41.78 (35.54-49.11)

147/5,985

11.81 (8.70-16.04)

41/5,773

20-25 yr

n.e.

0

0/ -

0

0/ -

CVD

0-1 yr

0.75 (0.69-0.82)

17.11 (16.23-18.04)

1,374/147

21.05 (20.08-22.07)

1,715/196

1-3 yr

0.75 (0.70-0.80)

19.12 (18.42-19.85)

2,749/733

23.77 (22.79-24.79)

2,164/613

3-5 yr

0.97 (0.88-1.06)

23.24 (22.35-24.17)

2,533/1,445

21.30 (19.83-22.88)

751/1,408

5-10 yr

1.34 (1.19-1.50)

29.05 (28.16-29.96)

4,011/2,540

18.73 (16.98-20.66)

400/2,223

10-15 yr

2.26 (1.42-3.57)

37.19 (34.85-39.68)

913/4,224

14.70 (9.49-22.79)

20/4,204

15-20 yr

1.45 (0.31-6.74)

43.36 (33.87-55.08)

63/5,762

48.47 (12.12-193.81)

2/ -

20-25 yr

n.e.

0

0/ -

0

0/ -

  1. PS – propensity score; *Final model: adjusted for age and propensity score; n.e. – no estimation.